...
机译:II期结肠癌患者的预后标记缺乏不匹配修复
Umea Univ Dept Surg &
Perioperat Sci Umea Sweden;
Umea Univ Dept Surg &
Perioperat Sci Umea Sweden;
Masaryk Mem Canc Inst Dept Oncol Pathol Brno Czech Republic;
Masaryk Mem Canc Inst Dept Comprehens Canc Care Brno Czech Republic;
Umea Univ Dept Med Biosci Pathol Umea Sweden;
Umea Univ Dept Surg &
Perioperat Sci Umea Sweden;
Charles Univ Prague Fac Hosp Pilsen Prague Czech Republic;
Charles Univ Prague Fac Hosp Pilsen Prague Czech Republic;
Univ Hosp Kralovske Vinohrady Dept Surg Prague Czech Republic;
Umea Univ Dept Surg &
Perioperat Sci Umea Sweden;
dMMR; Prognostic factors; Colon cancer; Stage II;
机译:II期结肠癌患者的预后标记缺乏不匹配修复
机译:从基于Folfox基辅助化疗的随机试验患者III阶段结肠癌患者缺乏DNA错配修复的预后影响。
机译:Girdin(GIV)表达作为错配修复熟练的II期结肠癌复发的预后标志
机译:四种标记物的联合表型可提高结肠癌患者的预后价值
机译:具有阶段I,II或III肺,结肠或直肠癌的退伍军人治疗发起的医院和患者特征
机译:DNA错配修复不足对基于FOLFOX的辅助化疗的随机试验对III期结肠癌患者的预后影响
机译:术前预养营养指标及其与阶段结肠癌患者全身炎症反应标志物关联的预后价值